Ho Jun Seol

Ho Jun Seol

Auto-generated profile, based on publicly available information

Ho Jun Seol

Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2015 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
JNJung-Hoon Noh
Jung-Hoon Noh
MLMin Ho Lee
Min Ho Lee
WKWon Seog Kim
Won Seog Kim
DLDo Hoon Lim
Do Hoon Lim
SKSung Tae Kim
Sung Tae Kim
HSHo Jun Seol
Ho Jun Seol

1 May 2016 in World Neurosurgery
Verified
Journal Article
Closed access
SLSeunghoon Lee
Seunghoon Lee
HSHo Jun Seol
Ho Jun Seol
KPKwan Park
Kwan Park
JLJung-Il Lee
Jung-Il Lee
DNDo-Hyun Nam
Do-Hyun Nam
YCYang-Sun Cho
Yang-Sun Cho

1 February 2022 in World Neurosurgery
Verified
Journal Article
Closed access
CHChang-Min Ha
Chang-Min Ha
SHSang Duk Hong
Sang Duk Hong
JCJung Won Choi
Jung Won Choi
HSHo Jun Seol
Ho Jun Seol
DNDo-Hyun Nam
Do-Hyun Nam
DKDoo-Sik Kong
Doo-Sik Kong

6 June 2017 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
SRSung Mo Ryu
Sung Mo Ryu
JLJung-Il Lee
Jung-Il Lee
KPKwan Park
Kwan Park
JCJung Won Choi
Jung Won Choi
DKDoo-Sik Kong
Doo-Sik Kong
HSHo Jun Seol
Ho Jun Seol

1 March 2021 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
MLMin Ho Lee
Min Ho Lee
KCkyung rae cho
kyung rae cho
JCJung Won Choi
Jung Won Choi
DKDoo-Sik Kong
Doo-Sik Kong
HSHo Jun Seol
Ho Jun Seol
JLJung-Il Lee
Jung-Il Lee
Objective : Immune checkpoint inhibitors (ICIs) are approved for treating non-small-cell lung cancer (NSCLC); however, the safety and efficacy of combined ICI and Gamma Knife radiosurgery (GKS) treatment remain undefined. In this study, we retrospectively analyzed patients treated with ICIs with or without GKS at our institute to manage patients with brain metastases from NSCLC. Methods : We retrospectively reviewed medical records of patients with brain metastases from NSCLC treated with ICIs between January 2015 and December 2017. Of 134 patients, 77 were assessable for brain responses and categorized into three groups as follows : group A, ICI alone (n=26); group B, ICI with concurrent GKS within 14 days (n=24); and group C, ICI with non-concurrent GKS (n=27). Results : The median follow-up duration after brain metastasis diagnosis was 19.1 months (range, 1-77). At the last follow-up, 53 patients (68.8%) died, 20 were alive, and four were lost to follow-up. The estimated median overall survival (OS) of all patients from the date of brain metastasis diagnosis was 20.0 months (95% confidence interval, 12.5-27.7) (10.0, 22.5, and 42.1 months in groups A, B, and C, respectively). The OS was shorter in group A than in group C (p=0.001). The intracranial disease progression-free survival (p=0.569), local progression-free survival (p=0.457), and complication rates did not significantly differ among the groups. Twelve patients showed leptomeningeal seeding (LMS) during follow-up. The 1-year LMS-free rate in treated with ICI alone group (69.1%) was significantly lower than that in treated with GKS before ICI treatment or within 14 days group (93.2%) (p=0.004). Conclusion : GKS with ICI showed no favorable OS outcome in treating brain metastasis from NSCLC. However, GKS with ICI did not increase the risk of complications. Furthermore, compared with ICI alone, GKS with ICI may be associated with a reduced incidence of LMS. Further understanding of the mechanism, which remains unknown, may help improve the quality of life of patients with brain metastasis.

4 May 2016 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
BKByung Sup Kim
Byung Sup Kim
HSHo Jun Seol
Ho Jun Seol
JLJung-Il Lee
Jung-Il Lee
HSHyung Jin Shin
Hyung Jin Shin
KPKwan Park
Kwan Park
YCYang-Sun Cho
Yang-Sun Cho